{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T12:23:27Z","timestamp":1788092607166,"version":"build-2803163510"},"reference-count":153,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T00:00:00Z","timestamp":1555027200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003006","name":"Eidgen\u00f6ssische Technische Hochschule Z\u00fcrich","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.phrs.2019.04.014","type":"journal-article","created":{"date-parts":[[2019,4,13]],"date-time":"2019-04-13T10:36:39Z","timestamp":1555151799000},"page":"104230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"special_numbering":"C","title":["Improvements of symptoms of Alzheimer`s disease by inhibition of the angiotensin system"],"prefix":"10.1016","volume":"154","author":[{"given":"Ursula","family":"Quitterer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said","family":"AbdAlla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2019.04.014_bib0005","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/475S2a","article-title":"Dementia: a problem of our age","volume":"475","author":"Abbott","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2019.04.014_bib0010","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s10072-016-2625-7","article-title":"Current pharmacotherapy and putative disease-modifying therapy for Alzheimer`s disease","volume":"37","author":"Kulshreshtha","year":"2016","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.phrs.2019.04.014_bib0015","first-page":"325","article-title":"Alzheimer disease","volume":"145","author":"Calderon-Garciduenas","year":"2017","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.phrs.2019.04.014_bib0020","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/brain\/awt062","article-title":"Brain amyloid-\u03b2 oligomers in ageing and Alzheimer`s disease","volume":"136","author":"Lesne","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.phrs.2019.04.014_bib0025","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/ana.410410106","article-title":"Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer`s disease","volume":"41","author":"Gomez-Isla","year":"1997","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.phrs.2019.04.014_bib0030","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer`s disease: progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.phrs.2019.04.014_bib0035","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/360672a0","article-title":"Mutation of the beta-amyloid precursor protein in familial Alzheimer`s disease increases beta-protein production","volume":"360","author":"Citron","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2019.04.014_bib0040","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1126\/science.274.5284.99","article-title":"Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice","volume":"274","author":"Hsiao","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.phrs.2019.04.014_bib0045","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1179\/016164103101202020","article-title":"Mouse models of Alzheimer`s disease: the long and filamentous road","volume":"25","author":"Phinney","year":"2003","journal-title":"Neurol. Res."},{"key":"10.1016\/j.phrs.2019.04.014_bib0050","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1126\/science.1058189","article-title":"Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP","volume":"293","author":"Lewis","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.phrs.2019.04.014_bib0055","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1126\/science.1062097","article-title":"Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils","volume":"293","author":"G\u00f6tz","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.phrs.2019.04.014_bib0060","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1126\/science.1064684","article-title":"Biomedicine. Tauists and beta-aptists united--well almost!","volume":"293","author":"Lee","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.phrs.2019.04.014_bib0065","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1001\/jamaneurol.2013.5847","article-title":"Amyloid-\u03b2 and tau: the trigger and bullet in Alzheimer disease pathogenesis","volume":"71","author":"Bloom","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.phrs.2019.04.014_bib0070","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/mp.2016.37","article-title":"Amyloid-\u03b2 and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer`s disease","volume":"22","author":"Pascoal","year":"2017","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2019.04.014_bib0075","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Alzheimer`s Disease Cooperative Study Steering Committee; Solanezumab Study Group. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer`s disease","volume":"370","author":"Doody","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.04.014_bib0080","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of Solanezumab for mild dementia due to Alzheimer`s disease","volume":"378","author":"Honig","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.04.014_bib0085","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Bapineuzumab 301 and 302 Clinical Trial Investigators. Two Phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer`s disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.04.014_bib0090","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13195-016-0189-7","article-title":"Bapineuzumab 3000 and 3001 Clinical Study Investigators. Bapineuzumab for mild to moderate Alzheimer`s disease in two global, randomized, phase 3 trials","volume":"8","author":"Vandenberghe","year":"2016","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.phrs.2019.04.014_bib0095","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/YCO.0000000000000041","article-title":"Is there still any hope for amyloid-based immunotherapy for Alzheimer`s disease?","volume":"27","author":"Panza","year":"2014","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.phrs.2019.04.014_bib0100","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1706441","article-title":"Randomized trial of verubecestat for mild-to-moderate Alzheimer`s disease","volume":"378","author":"Egan","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.04.014_bib0105","doi-asserted-by":"crossref","first-page":"j845","DOI":"10.1136\/bmj.j845","article-title":"Merck ends trial of potential Alzheimer`s drug verubecestat","volume":"356","author":"Hawkes","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2019.04.014_bib0110","doi-asserted-by":"crossref","first-page":"i6771","DOI":"10.1136\/bmj.i6771","article-title":"Solanezumab and the amyloid hypothesis for Alzheimer`s disease","volume":"355","author":"Le Couteur","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2019.04.014_bib0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-016-0227-5","article-title":"Tau passive immunization inhibits not only tau but also A\u03b2 pathology","volume":"9","author":"Dai","year":"2017","journal-title":"Alzheimers Res. Ther."},{"issue":"2018","key":"10.1016\/j.phrs.2019.04.014_bib0120","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.trci.2018.03.009","article-title":"Alzheimer`s disease drug development pipeline","volume":"4","author":"Cummings","year":"2018","journal-title":"Alzheimers Dement. N. Y. (N Y)"},{"key":"10.1016\/j.phrs.2019.04.014_bib0125","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1111\/j.1471-4159.1982.tb07930.x","article-title":"Angiotensin converting enzyme in Alzheimer`s disease increased activity in caudate nucleus and cortical areas","volume":"38","author":"Arregui","year":"1982","journal-title":"J. Neurochem."},{"key":"10.1016\/j.phrs.2019.04.014_bib0130","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0197-4580(00)00259-1","article-title":"Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer`s dementia","volume":"22","author":"Savaskan","year":"2001","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.phrs.2019.04.014_bib0135","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2990.2007.00885.x","article-title":"Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer`s disease, and relationship of perivascular ACE-1 to cerebral amyloid angiopathy","volume":"34","author":"Miners","year":"2008","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.phrs.2019.04.014_bib0140","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1152\/physrev.00038.2017","article-title":"Angiotensin II signal transduction: an update on mechanisms of physiology and pathophysiology","volume":"98","author":"Forrester","year":"2018","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.phrs.2019.04.014_bib0145","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3389\/fnagi.2017.00129","article-title":"Brain renin-angiotensin system and microglial polarization: implications for aging and neurodegeneration","volume":"9","author":"Labandeira-Garcia","year":"2017","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.phrs.2019.04.014_bib0150","doi-asserted-by":"crossref","first-page":"37644","DOI":"10.1074\/jbc.M508460200","article-title":"Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor","volume":"280","author":"Hemming","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2019.04.014_bib0155","doi-asserted-by":"crossref","first-page":"30471","DOI":"10.1074\/jbc.M605827200","article-title":"Regulation of steady-state beta-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme","volume":"281","author":"Eckman","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2019.04.014_bib0160","doi-asserted-by":"crossref","first-page":"16917","DOI":"10.3390\/ijms140816917","article-title":"ACE inhibition with captopril retards the development of signs of neurodegeneration in an animal model of Alzheimer`s disease","volume":"14","author":"AbdAlla","year":"2013","journal-title":"Int. J. Mol. Sci."},{"issue":"2015","key":"10.1016\/j.phrs.2019.04.014_bib0165","first-page":"917156","article-title":"Inhibition of ACE retards tau hyperphosphorylation and signs of neuronal degeneration in aged rats subjected to chronic mild stress","author":"AbdAlla","year":"2015","journal-title":"Biomed Res. Int."},{"key":"10.1016\/j.phrs.2019.04.014_bib0170","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3233\/JAD-2009-1096","article-title":"Early changes in hippocampal Eph receptors precede the onset of memory decline in mouse models of Alzheimer`s disease","volume":"17","author":"Simon","year":"2009","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.phrs.2019.04.014_bib0175","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1096\/fj.11-182873","article-title":"Perindopril, a centrally active angiotensin-converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer`s disease","volume":"25","author":"Dong","year":"2011","journal-title":"FASEB J."},{"key":"10.1016\/j.phrs.2019.04.014_bib0180","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.3233\/JAD-171119","article-title":"The coming of age of the angiotensin hypothesis in Alzheimer`s disease: progress toward disease prevention and treatment?","volume":"62","author":"Kehoe","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.phrs.2019.04.014_bib0185","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3389\/fphys.2013.00148","article-title":"Microarray gene expression profiling reveals antioxidant-like effects of angiotensin II inhibition in atherosclerosis","volume":"4","author":"Abd Alla","year":"2013","journal-title":"Front. Physiol."},{"key":"10.1016\/j.phrs.2019.04.014_bib0190","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1357-2725(02)00306-0","article-title":"The brain renin-angiotensin system: location and physiological roles","volume":"35","author":"McKinley","year":"2003","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.phrs.2019.04.014_bib0195","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00424-012-1102-2","article-title":"The brain renin-angiotensin system: a diversity of functions and implications for CNS diseases","volume":"465","author":"Wright","year":"2013","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.phrs.2019.04.014_bib0200","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1161\/01.HYP.0000179088.57586.26","article-title":"Oxidative stress mediates angiotensin II-dependent stimulation of sympathetic nerve activity","volume":"46","author":"Campese","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2019.04.014_bib0205","article-title":"Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension","volume":"8","author":"Li","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.phrs.2019.04.014_bib0210","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1161\/01.STR.24.10.1561","article-title":"Angiotensin converting enzyme inhibitors attenuate ischemic brain metabolism in hypertensive rats","volume":"24","author":"Sadoshima","year":"1993","journal-title":"Stroke"},{"key":"10.1016\/j.phrs.2019.04.014_bib0215","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1161\/01.RES.0000043501.47934.FA","article-title":"Superoxide mediates the actions of angiotensin II in the central nervous system","volume":"91","author":"Zimmerman","year":"2002","journal-title":"Circ. Res."},{"key":"10.1016\/j.phrs.2019.04.014_bib0220","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.biopsych.2013.08.024","article-title":"Angiotensin type 1 receptor inhibition enhances the extinction of fear memory","volume":"75","author":"Marvar","year":"2014","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2019.04.014_bib0225","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1161\/HYPERTENSIONAHA.116.08188","article-title":"Monotherapy with major antihypertensive drug classes and risk of hospital admissions for mood disorders","volume":"68","author":"Boal","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2019.04.014_bib0230","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12916-017-0916-3","article-title":"The renin-angiotensin system: a possible new target for depression","volume":"15","author":"Vian","year":"2017","journal-title":"BMC Med."},{"key":"10.1016\/j.phrs.2019.04.014_bib0235","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s13311-018-0646-z","article-title":"Angiotensin type 1 receptor antagonists protect against alpha-synuclein-induced neuroinflammation and dopaminergic neuron death","volume":"15","author":"Rodriguez-Perez","year":"2018","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.phrs.2019.04.014_bib0240","doi-asserted-by":"crossref","first-page":"e98961","DOI":"10.1371\/journal.pone.0098961","article-title":"Antihypertensive agents and risk of Parkinson`s disease: a nationwide cohort study","volume":"9","author":"Lee","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2019.04.014_bib0245","doi-asserted-by":"crossref","first-page":"16024","DOI":"10.1038\/npjamd.2016.24","article-title":"Deficiency of the angiotensin-converting enzyme 2 causes deterioration of cognitive function","volume":"2","author":"Wang","year":"2016","journal-title":"NPJ Aging Mech. Dis."},{"key":"10.1016\/j.phrs.2019.04.014_bib0250","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11906-014-0512-2","article-title":"Neuroprotective mechanisms of the ACE2-angiotensin-(1-7)-Mas axis in stroke","volume":"17","author":"Bennion","year":"2015","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.phrs.2019.04.014_bib0255","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.neuroscience.2017.01.027","article-title":"Angiotensin-(1-7) administration attenuates Alzheimer`s disease-like neuropathology in rats with streptozotocin-induced diabetes via Mas receptor activation","volume":"346","author":"Chen","year":"2017","journal-title":"Neuroscience"},{"key":"10.1016\/j.phrs.2019.04.014_bib0260","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1161\/01.HYP.31.1.362","article-title":"Metabolism of angiotensin-(1-7) by angiotensin-converting enzyme","volume":"31","author":"Chappell","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2019.04.014_bib0265","doi-asserted-by":"crossref","first-page":"39721","DOI":"10.1074\/jbc.M105253200","article-title":"The angiotensin II AT2 receptor is an AT1 receptor antagonist","volume":"276","author":"AbdAlla","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2019.04.014_bib0270","doi-asserted-by":"crossref","first-page":"62S","DOI":"10.1016\/S0895-7061(00)00274-0","article-title":"The role of the AT2 receptor in hypertension","volume":"13","author":"Siragy","year":"2000","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.phrs.2019.04.014_bib0275","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jash.2015.01.010","article-title":"Direct angiotensin II type 2 receptor stimulation by compound 21 prevents vascular dementia","volume":"9","author":"Iwanami","year":"2015","journal-title":"J. Am. Soc. Hypertens."},{"key":"10.1016\/j.phrs.2019.04.014_bib0280","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1447-0594.2012.00900.x","article-title":"Effect of angiotensin II type 2 receptor on stroke, cognitive impairment and neurodegenerative diseases","volume":"13","author":"Mogi","year":"2013","journal-title":"Geriatr. Gerontol. Int."},{"key":"10.1016\/j.phrs.2019.04.014_bib0285","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.nbd.2007.01.004","article-title":"Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid beta-protein metabolism in mouse models of Alzheimer disease","volume":"26","author":"Hemming","year":"2007","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.phrs.2019.04.014_bib0290","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1097\/00029330-200811020-00019","article-title":"Altered angiotensin-converting enzyme and its effects on the brain in a rat model of Alzheimer disease","volume":"121","author":"Hou","year":"2008","journal-title":"Chin. Med. J. (Engl.)."},{"key":"10.1016\/j.phrs.2019.04.014_bib0295","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1007\/s11481-016-9703-8","article-title":"Angiotensin converting enzyme inhibitors ameliorate brain inflammation associated with microglial activation: possible implications for Alzheimer`s disease","volume":"11","author":"Torika","year":"2016","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.phrs.2019.04.014_bib0300","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1021\/acschemneuro.5b00274","article-title":"Perindopril attenuates lipopolysaccharide-induced amyloidogenesis and memory impairment by suppression of oxidative stress and RAGE activation","volume":"7","author":"Goel","year":"2016","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.phrs.2019.04.014_bib0305","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.brainres.2013.05.045","article-title":"Recombinant soluble neprilysin reduces amyloid-beta accumulation and improves memory impairment in Alzheimer`s disease mice","volume":"1529","author":"Park","year":"2013","journal-title":"Brain Res."},{"key":"10.1016\/j.phrs.2019.04.014_bib0310","doi-asserted-by":"crossref","first-page":"24540","DOI":"10.1074\/jbc.M007579200","article-title":"Degradation of the Alzheimer`s amyloid beta peptide by endothelin-converting enzyme","volume":"276","author":"Eckman","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2019.04.014_bib0315","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1074\/jbc.C200642200","article-title":"Alzheimer`s disease beta-amyloid peptide is increased in mice deficient in endothelin-converting enzyme","volume":"278","author":"Eckman","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2019.04.014_bib0320","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.3233\/JAD-142463","article-title":"Neprilysin deficiency alters the neuropathological and behavioral phenotype in the 5XFAD mouse model of Alzheimer`s disease","volume":"44","author":"H\u00fcttenrauch","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.phrs.2019.04.014_bib0325","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.bbi.2017.04.001","article-title":"Intranasal telmisartan ameliorates brain pathology in five familial Alzheimer`s disease mice","volume":"64","author":"Torika","year":"2017","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.phrs.2019.04.014_bib0330","doi-asserted-by":"crossref","first-page":"12059","DOI":"10.1038\/srep12059","article-title":"Angiotensin type 1a receptor deficiency decreases amyloid \u03b2-protein generation and ameliorates brain amyloid pathology","volume":"5","author":"Liu","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2019.04.014_bib0335","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1172\/JCI31547","article-title":"Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease","volume":"117","author":"Wang","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2019.04.014_bib0340","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1089\/rej.2009.0944","article-title":"Protective effects of intranasal losartan in the APP\/PS1 transgenic mouse model of Alzheimer disease","volume":"13","author":"Danielyan","year":"2010","journal-title":"Rejuvenation Res."},{"key":"10.1016\/j.phrs.2019.04.014_bib0345","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3233\/JAD-150487","article-title":"Alzheimer`s Disease Neuroimaging Initiative. Older adults taking AT1-receptor blockers exhibit reduced cerebral amyloid retention","volume":"50","author":"Nation","year":"2016","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.phrs.2019.04.014_bib0350","doi-asserted-by":"crossref","first-page":"8641","DOI":"10.1074\/jbc.M111.279133","article-title":"Phosphorylation of amyloid-beta peptide at serine 8 attenuates its clearance via insulin-degrading and angiotensin-converting enzymes","volume":"287","author":"Kumar","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2019.04.014_bib0355","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI114844","article-title":"An insertion\/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels","volume":"86","author":"Rigat","year":"1990","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2019.04.014_bib0360","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1517\/14622416.1.2.153","article-title":"The DD-ACE genotype and cardiovascular disease","volume":"1","author":"Butler","year":"2000","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.phrs.2019.04.014_bib0365","article-title":"Angiotensin-converting enzyme insertion\/deletion polymorphism is not a major determining factor in the development of sporadic Alzheimer disease: evidence from an updated meta-analysis","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2019.04.014_bib0370","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3233\/JAD-2011-101914","article-title":"A multi-centre study of ACE and the risk of late-onset Alzheimer`s disease","volume":"24","author":"Belbin","year":"2011","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.phrs.2019.04.014_bib0375","article-title":"Renin-angiotensin system gene expression and neurodegenerative diseases","volume":"17","author":"Goldstein","year":"2016","journal-title":"J. Renin. Syst."},{"key":"10.1016\/j.phrs.2019.04.014_bib0380","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41588-019-0358-2","article-title":"Genetic meta-analysis of diagnosed Alzheimer`s disease identifies new risk loci and implicates Abeta, tau immunity and lipid processing","volume":"51","author":"Kunkle","year":"2019","journal-title":"Nat. Genet."},{"key":"10.1016\/j.phrs.2019.04.014_bib0385","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3233\/JAD-170944","article-title":"Associations of angiotensin converting enzyme-1 and angiotensin II blood levels and cognitive function","volume":"63","author":"Yasar","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.phrs.2019.04.014_bib0390","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer`s disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.phrs.2019.04.014_bib0395","doi-asserted-by":"crossref","first-page":"15056","DOI":"10.1038\/nrdp.2015.56","article-title":"Alzheimer`s disease","volume":"1","author":"Masters","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.phrs.2019.04.014_bib0400","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1159\/000487079","article-title":"An estimate of attributable cases of Alzheimer disease and vascular dementia due to modifiable risk factors: the impact of primary prevention in Europe and in Italy","volume":"8","author":"Mayer","year":"2018","journal-title":"Dement. Geriatr. Cogn. Dis. Extra"},{"key":"10.1016\/j.phrs.2019.04.014_bib0405","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1172\/JCI36703","article-title":"Disruption of the Ang II type 1 receptor promotes longevity in mice","volume":"119","author":"Benigni","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2019.04.014_bib0410","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s11357-016-9948-4","article-title":"Combined statin and angiotensin-converting enzyme (ACE) inhibitor treatment increases the lifespan of long-lived F1 male mice","volume":"38","author":"Spindler","year":"2016","journal-title":"Age Dordr. (Dordr)"},{"key":"10.1016\/j.phrs.2019.04.014_bib0415","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00424-009-0725-4","article-title":"Angiotensin receptors as determinants of life span","volume":"459","author":"Cassis","year":"2010","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.phrs.2019.04.014_bib0420","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11906-012-0323-2","article-title":"The renin angiotensin aldosterone system and insulin resistance in humans","volume":"15","author":"Underwood","year":"2013","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.phrs.2019.04.014_bib0425","doi-asserted-by":"crossref","first-page":"R974","DOI":"10.1152\/ajpregu.00147.2007","article-title":"Improvement of insulin sensitivity by antagonism of the renin-angiotensin system","volume":"293","author":"Henriksen","year":"2007","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.phrs.2019.04.014_bib0430","doi-asserted-by":"crossref","first-page":"E435","DOI":"10.1152\/ajpendo.00391.2014","article-title":"Modulation of glucose metabolism by the renin-angiotensin-aldosterone system","volume":"308","author":"Favre","year":"2015","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2019.04.014_bib0435","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s40265-016-0674-0","article-title":"Insulin resistance and neurodegeneration: progress towards the development of new therapeutics for Alzheimer`s disease","volume":"77","author":"de la Monte","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2019.04.014_bib0440","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3233\/JAD-180297","article-title":"Metabolic syndrome and amyloid accumulation in the aging brain","volume":"65","author":"Gomez","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.phrs.2019.04.014_bib0445","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jalz.2012.06.007","article-title":"Renin-angiotensin system blockers affect cognitive decline and serum adipocytokines in Alzheimer`s disease","volume":"9","author":"Furiya","year":"2013","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.phrs.2019.04.014_bib0450","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/00005344-199810000-00014","article-title":"ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients","volume":"32","author":"Fogari","year":"1998","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.phrs.2019.04.014_bib0455","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0895-7061(01)02340-8","article-title":"Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients","volume":"15","author":"Fogari","year":"2002","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.phrs.2019.04.014_bib0460","doi-asserted-by":"crossref","first-page":"6531","DOI":"10.1073\/pnas.0802690105","article-title":"Mice lacking angiotensin-converting enzyme have increased energy expenditure, with reduced fat mass and improved glucose clearance","volume":"105","author":"Jayasooriya","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.phrs.2019.04.014_bib0465","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1210\/en.2005-0003","article-title":"Attenuation of diet-induced weight gain and adiposity through increased energy expenditure in mice lacking angiotensin II type 1a receptor","volume":"146","author":"Kouyama","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.phrs.2019.04.014_bib0470","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.physbeh.2009.05.009","article-title":"Angiotensin converting enzyme inhibition lowers body weight and improves glucose tolerance in C57BL\/6J mice maintained on a high fat diet","volume":"98","author":"Weisinger","year":"2009","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.phrs.2019.04.014_bib0475","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.peptides.2012.06.005","article-title":"Captopril intake decreases body weight gain via angiotensin-(1-7)","volume":"37","author":"Oh","year":"2012","journal-title":"Peptides"},{"key":"10.1016\/j.phrs.2019.04.014_bib0480","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1161\/CIRCRESAHA.118.313260","article-title":"Neurovascular and cognitive dysfunction in hypertension","volume":"124","author":"Iadecola","year":"2019","journal-title":"Circ. Res."},{"key":"10.1016\/j.phrs.2019.04.014_bib0485","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3389\/fnagi.2018.00073","article-title":"Hypertension accelerates Alzheimer`s disease-related pathologies in pigs and 3xTg mice","volume":"10","author":"Shih","year":"2018","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.phrs.2019.04.014_bib0490","doi-asserted-by":"crossref","first-page":"e517","DOI":"10.1212\/WNL.0000000000005951","article-title":"Late-life blood pressure association with cerebrovascular and Alzheimer disease pathology","volume":"91","author":"Arvanitakis","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.phrs.2019.04.014_bib0495","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/ene.13374","article-title":"Alzheimer`s Disease Neuroimaging Initiative. Hypertension is associated with worse cognitive function and hippocampal hypometabolism in Alzheimer`s disease","volume":"24","author":"Moonga","year":"2017","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.phrs.2019.04.014_bib0500","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/j.1532-5415.2007.01233.x","article-title":"Age-varying association between blood pressure and risk of dementia in those aged 65 and older: a community-based prospective cohort study","volume":"55","author":"Li","year":"2007","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.phrs.2019.04.014_bib0505","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0006-3223(98)00101-2","article-title":"Evidence of a possible role of altered angiotensin function in the treatment, but not etiology, of depression","volume":"45","author":"Gard","year":"1999","journal-title":"Biol. Psychiatry"},{"issue":"2012","key":"10.1016\/j.phrs.2019.04.014_bib0510","article-title":"Roles of brain angiotensin II in cognitive function and dementia","volume":"169649","author":"Mogi","year":"2012","journal-title":"Int. J. Hypertens."},{"key":"10.1016\/j.phrs.2019.04.014_bib0515","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/00005344-199008000-00009","article-title":"Angiotensin II inhibits cortical cholinergic function: implications for cognition","volume":"16","author":"Barnes","year":"1990","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.phrs.2019.04.014_bib0520","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0006-8993(90)90294-L","article-title":"Angiotensin II inhibits acetylcholine release from human temporal cortex: implications for cognition","volume":"507","author":"Barnes","year":"1990","journal-title":"Brain Res."},{"issue":"Suppl. 6","key":"10.1016\/j.phrs.2019.04.014_bib0525","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1097\/00005344-199219006-00011","article-title":"Angiotensin-converting enzyme inhibition, angiotensin, and cognition","volume":"19","author":"Barnes","year":"1992","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.phrs.2019.04.014_bib0530","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.brainres.2011.09.016","article-title":"Effect of a centrally active angiotensin converting enzyme inhibitor, perindopril, on cognitive performance in chronic cerebral hypo-perfusion rats","volume":"1421","author":"Yamada","year":"2011","journal-title":"Brain Res."},{"key":"10.1016\/j.phrs.2019.04.014_bib0535","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.brainres.2010.07.006","article-title":"Effect of a centrally active angiotensin-converting enzyme inhibitor, perindopril, on cognitive performance in a mouse model of Alzheimer`s disease","volume":"1352","author":"Yamada","year":"2010","journal-title":"Brain Res."},{"key":"10.1016\/j.phrs.2019.04.014_bib0540","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.pbb.2013.10.027","article-title":"The effects of perindopril on cognitive impairment induced by d-galactose and aluminium trichloride via inhibition of acetylcholinesterase activity and oxidative stress","volume":"114-115","author":"Yang","year":"2013","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.phrs.2019.04.014_bib0545","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1161\/HYPERTENSIONAHA.109.138586","article-title":"Angiotensin receptor blocker prevented beta-amyloid-induced cognitive impairment associated with recovery of neurovascular coupling","volume":"54","author":"Takeda","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2019.04.014_bib0550","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13195-017-0255-9","article-title":"Alzheimer`s Disease Neuroimaging Initiative. Memory is preserved in older adults taking AT1 receptor blockers","volume":"9","author":"Ho","year":"2017","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.phrs.2019.04.014_bib0555","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/archinternmed.2009.175","article-title":"Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study","volume":"169","author":"Sink","year":"2009","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.phrs.2019.04.014_bib0560","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jocn.2016.02.036","article-title":"The association of renin-angiotensin system blockade use with the risks of cognitive impairment of aging and Alzheimer`s disease: a meta-analysis","volume":"33","author":"Zhuang","year":"2016","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.phrs.2019.04.014_bib0565","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1111\/jgs.12415","article-title":"Angiotensin-converting enzyme inhibitors and Alzheimer`s disease progression in older adults: results from the R\u00e9seau sur la Maladie d`Alzheimer Francais cohort","volume":"61","author":"Soto","year":"2013","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.phrs.2019.04.014_bib0570","doi-asserted-by":"crossref","first-page":"e002881","DOI":"10.1136\/bmjopen-2013-002881","article-title":"Effects of centrally acting ACE inhibitors on the rate of cognitive decline in dementia","volume":"3","author":"Gao","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.phrs.2019.04.014_bib0575","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3233\/JAD-131694","article-title":"Effects of centrally acting angiotensin converting enzyme inhibitors on functional decline in patients with Alzheimer`s disease","volume":"40","author":"O`Caoimh","year":"2014","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.phrs.2019.04.014_bib0580","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1192\/bjpo.bp.116.004184","article-title":"Associations of centrally acting ACE inhibitors with cognitive decline and survival in Alzheimer`s disease","volume":"3","author":"Fazal","year":"2017","journal-title":"BJPsych Open"},{"key":"10.1016\/j.phrs.2019.04.014_bib0585","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jagp.2012.08.017","article-title":"Angiotensin converting enzyme inhibitors and Alzheimer disease in the presence of the apolipoprotein E4 allele","volume":"22","author":"Qiu","year":"2014","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.phrs.2019.04.014_bib0590","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2174\/1567205014666171016101816","article-title":"Pharmacogenetics of angiotensin-converting enzyme inhibitors in patients with Alzheimer`s disease dementia","volume":"15","author":"de Oliveira","year":"2018","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.phrs.2019.04.014_bib0595","doi-asserted-by":"crossref","first-page":"R25","DOI":"10.1152\/ajpregu.2001.280.1.R25","article-title":"Glucocorticoid regulation of angiotensin-converting enzyme in primary culture of cardiac fibroblasts","volume":"280","author":"Barreto-Chaves","year":"2001","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.phrs.2019.04.014_bib0600","first-page":"L645","article-title":"Stimulation of bovine pulmonary artery endothelial cell ACE by dexamethasone: involvement of steroid receptors","volume":"263","author":"Dasarathy","year":"1992","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.phrs.2019.04.014_bib0605","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/01.HYP.25.3.343","article-title":"Glucocorticoids induce angiotensin-converting enzyme expression in vascular smooth muscle","volume":"25","author":"Fishel","year":"1995","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2019.04.014_bib0610","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.bbr.2011.01.005","article-title":"Chronic mild stress in mice promotes cognitive impairment and CDK5-dependent tau hyperphosphorylation","volume":"220","author":"Cuadrado-Tejedor","year":"2011","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.phrs.2019.04.014_bib0615","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/j.1476-5381.2011.01602.x","article-title":"Stress-induced anhedonia is associated with an increase in Alzheimer`s disease-related markers","volume":"165","author":"Briones","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2019.04.014_bib0620","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.pbb.2008.08.003","article-title":"Changes in glutamate decarboxylase enzyme activity and tau-protein phosphorylation in the hippocampus of old rats exposed to chronic mild stress: reversal with the neuronal nitric oxide synthase inhibitor 7-nitroindazole","volume":"91","author":"El-faramawy","year":"2009","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.phrs.2019.04.014_bib0625","doi-asserted-by":"crossref","first-page":"6566","DOI":"10.1074\/jbc.M808277200","article-title":"Dominant negative AT2 receptor oligomers induce G-protein arrest and symptoms of neurodegeneration","volume":"284","author":"AbdAlla","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2019.04.014_bib0630","doi-asserted-by":"crossref","first-page":"6554","DOI":"10.1074\/jbc.M807746200","article-title":"Angiotensin II AT2 receptor oligomers mediate G-protein dysfunction in an animal model of Alzheimer`s Disease","volume":"284","author":"AbdAlla","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2019.04.014_bib0635","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ynstr.2018.04.002","article-title":"The relationship between stress and Alzheimer`s disease","volume":"8","author":"Justice","year":"2018","journal-title":"Neurobiol. Stress"},{"key":"10.1016\/j.phrs.2019.04.014_bib0640","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ynstr.2018.05.003","article-title":"Chronic stress as a risk factor for Alzheimer`s disease: roles of microglia-mediated synaptic remodelling, inflammation, and oxidative stress","volume":"9","author":"Bisht","year":"2018","journal-title":"Neurobiol. Stress"},{"key":"10.1016\/j.phrs.2019.04.014_bib0645","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000318607","article-title":"Altered reneal expression of angiotensin II receptors, renin receptor, and ACE-2 precede the development of renal fibrosis in aging rats","volume":"32","author":"Schulman","year":"2010","journal-title":"Am. J. Nephrol."},{"issue":"2016","key":"10.1016\/j.phrs.2019.04.014_bib0650","article-title":"Age-associated changes in the vascular renin-angiotensin system in mice","volume":"6731093","author":"Yoon","year":"2016","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.phrs.2019.04.014_bib0655","first-page":"141","article-title":"Changes in the renin-angiotensin-aldosterone system in elderly patients with chronic ischemic heart disease. 3. The renin-angiotensin-aldosterone system in elderly patients with ischemic heart disease without cardiovascular failure","volume":"44","author":"Korkusko","year":"1989","journal-title":"Z. Alternsforsch."},{"key":"10.1016\/j.phrs.2019.04.014_bib0660","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.cell.2012.02.046","article-title":"Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model","volume":"149","author":"Verret","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2019.04.014_bib0665","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1007\/s12031-011-9648-6","article-title":"Brain expression of Kv3 subunits during development, adulthood and aging and in a murine model of Alzheimer`s disease","volume":"46","author":"Boda","year":"2012","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.phrs.2019.04.014_bib0670","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1172\/JCI41709","article-title":"Angiotensin II sustains brain inflammation in mice via TGF-beta","volume":"120","author":"Lanz","year":"2010","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2019.04.014_bib0675","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/bpa.12538","article-title":"Diversity of astroglial responses across human neurodegenerative disorders and brain aging","volume":"27","author":"Ferrer","year":"2017","journal-title":"Brain Pathol."},{"key":"10.1016\/j.phrs.2019.04.014_bib0680","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.biopha.2017.08.042","article-title":"Neuroprotection of bradykinin\/bradykinin B2 receptor system in cerebral ischemia","volume":"94","author":"Ji","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.phrs.2019.04.014_bib0685","doi-asserted-by":"crossref","first-page":"e008121","DOI":"10.1161\/JAHA.117.008121","article-title":"Beneficial effect of Mas receptor deficiency on vascular cognitive impairment in the presence of angiotensin II type 2 receptor","volume":"7","author":"Higaki","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.phrs.2019.04.014_bib0690","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.taap.2013.12.001","article-title":"Chronic infusion of enalaprilat into hypothalamic paraventricular nucleus attenuates angiotensin II-induced hypertension and cardiac hypertrophy by restoring neurotransmitters and cytokines","volume":"274","author":"Kang","year":"2014","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.phrs.2019.04.014_bib0695","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s12012-012-9184-9","article-title":"Renin-angiotensin system modulates neurotransmitters in the paraventricular nucleus and contributes to angiotensin II-induced hypertensive response","volume":"13","author":"Qi","year":"2013","journal-title":"Cardiovasc. Toxicol."},{"key":"10.1016\/j.phrs.2019.04.014_bib0700","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1016\/j.febslet.2012.09.004","article-title":"Central angiotensin II-induced Alzheimer-like tau phosphorylation in normal rat brains","volume":"586","author":"Tian","year":"2012","journal-title":"FEBS Lett."},{"key":"10.1016\/j.phrs.2019.04.014_bib0705","doi-asserted-by":"crossref","first-page":"17721","DOI":"10.1074\/jbc.M800013200","article-title":"Hydrogen peroxide promotes Abeta production through JNK-dependent activation of gamma-secretase","volume":"283","author":"Shen","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2019.04.014_bib0710","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/da7ad86d-a5dc-4b03-981b-e44a2392c67b","article-title":"Mild oxidative stress induces redistribution of BACE1 in non-apoptotic conditions and promotes the amyloidogenic processing of Alzheimer\u00b4s disease amyloid precursor protein","volume":"8","author":"Tan","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2019.04.014_bib0715","article-title":"Central angiotensin II stimulation promotes beta amyloid production in Sprague Dawley rats","volume":"6","author":"Zhu","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2019.04.014_bib0720","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1086\/302553","article-title":"Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum","volume":"65","author":"Campion","year":"1999","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.phrs.2019.04.014_bib0725","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/GIM.0b013e31816b64dc","article-title":"Genetic aspects of Alzheimer disease","volume":"10","author":"Bird","year":"2008","journal-title":"Genet. Med."},{"key":"10.1016\/j.phrs.2019.04.014_bib0730","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1017\/S0317167100013949","article-title":"Early-onset familial Alzheimer`s disease (EOFAD)","volume":"39","author":"Wu","year":"2012","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.phrs.2019.04.014_bib0735","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10522-015-9618-4","article-title":"Mitochondrial dysfunction: the missing link between aging and sporadic Alzheimer`s disease","volume":"17","author":"Grimm","year":"2016","journal-title":"Biogerontology"},{"key":"10.1016\/j.phrs.2019.04.014_bib0740","doi-asserted-by":"crossref","first-page":"C570","DOI":"10.1152\/ajpcell.00353.2014","article-title":"A neuroprotective role of the NMDA receptor subunit GluN3A (NR3A) in ischemic stroke of the adult mouse","volume":"308","author":"Lee","year":"2015","journal-title":"Am. J. Physiol., Cell Physiol."},{"key":"10.1016\/j.phrs.2019.04.014_bib0745","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1042\/AN20130009","article-title":"The GluN3A subunit exerts a neuroprotective effect in brain ischemia and the hypoxia process","volume":"5","author":"Wang","year":"2013","journal-title":"ASN Neuro"},{"key":"10.1016\/j.phrs.2019.04.014_bib0750","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.neuroimage.2012.06.048","article-title":"Hippocampal CA1 apical neuropil atrophy and memory performance in Alzheimer`s disease","volume":"63","author":"Kerchner","year":"2012","journal-title":"Neuroimage"},{"key":"10.1016\/j.phrs.2019.04.014_bib0755","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(94)92338-8","article-title":"Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer`s disease","volume":"344","author":"West","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2019.04.014_bib0760","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1212\/01.WNL.0000140705.23869.E9","article-title":"Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression","volume":"63","author":"Ohrui","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.phrs.2019.04.014_bib0765","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41582-018-0116-6","article-title":"A critical appraisal of amyloid-beta-targeting therapies for Alzheimer disease","volume":"15","author":"Panza","year":"2019","journal-title":"Nat. Rev. Neurol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661818319509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661818319509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:03:23Z","timestamp":1760911403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661818319509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":153,"alternative-id":["S1043661818319509"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2019.04.014","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improvements of symptoms of Alzheimer`s disease by inhibition of the angiotensin system","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2019.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104230"}}